Dietary polyamine supplement
Spermidine
Spermidine is a polyamine for which the app lists a half-life of 6 hours; no half-life figure appeared in the trial texts read, and a 15 mg/d crossover trial found no rise in plasma spermidine.1
Spermidine after one dose: 50% at ~6 h, 25% at 12 h, 12.5% at 18 h.
Drawn from the half-life in the app's model, ~6 h. The model's figures
- Compound
- Spermidine
- Symbol
- SPD
- Family
- Supplements
- Parts
- 13
- References
- 12
- Checked
- Last reviewed . Sources are listed below.
Overview
Spermidine is a linear triamine that one document describes as "present in all tissues of the human body".2 The app lists it as a supplement in the autophagy inducer sub-category, taken by mouth. In the European Union, a spermidine-rich wheat germ extract from Triticum aestivum is on the Union list of novel foods, after TLL The Longevity Labs GmbH notified the Commission in 2017.3 In the United States, the same company submitted GRAS Notice 889 for a spermidine-rich wheat germ extract.2
Diet supplies spermidine already: Pekar and colleagues (Wiener Klinische Wochenschrift, 2021) write that wheat germ and whole grain are the highest source they list, at 243 mg/kg, and that average daily intake "has been described as approximately 10 mg per person in developed countries".4 The SmartAge trial authors (Schwarz and colleagues, JAMA Network Open, 2022) describe the capsule amount they gave as an increase in daily supply of about 10%.5 The app grades the evidence as moderate and notes an epidemiological link to longevity in humans. That link comes from a dietary cohort study (Kiechl and colleagues, American Journal of Clinical Nutrition, 2018), not from a supplement trial.6
How it works
The SmartAge authors describe polyamines, "particularly spermidine", as "essential for multiple cellular processes, including autophagy and the maintenance of cellular homeostasis".5 Wirth and colleagues (Cortex, 2018) describe spermidine as "an autophagy-enhancing agent" and cite memory protection in "aging model organisms"; that statement concerns animal work, not the human trial it introduces.7 In the vaccine pilot (Alsaleh and colleagues, Aging Cell, 2026), single-cell RNA sequencing after treatment "revealed increased expression of TFEB targets and autophagy-related genes in B cells"; the authors read this as "in line with elevated autophagic flux".8 That is a measurement in blood cells from a pilot of 40 adults, not a direct measurement of autophagy in tissues.8 Senekowitsch and colleagues (Nutrients, 2023) suggest that oral spermidine is "presystemically converted into spermine, which then enters systemic circulation", and that effects of spermidine may be "at least in part attributable to its metabolite, spermine".1
Half-life and pharmacokinetics
Values from the Milligram app's model.
- Half-life
- ~6 h
- Bioavailability
- 70%
- Typical dose
- 1–10 mg/day
- Route
- Oral
- Time to peak
- ~2 h
The second column of the table holds the app's own figures, shown beside what the sources report.
| Parameter | App's figure | Reported in the sources |
|---|---|---|
| Half-life | ~6 h | No half-life figure appeared in the trial texts read; Senekowitsch and colleagues sampled plasma across two 5-day phases and report AUC, cmax and tmax instead1 |
| Bioavailability | 70% | After 15 mg/d for 5 days in 12 healthy volunteers, plasma spermidine AUC0-tlast was 1533 (SD 406.2) h·ng/mL on placebo and 1567 (SD 412.6) on spermidine, p = 0.7819; plasma spermine was 583.8 (SD 124.8) and 633.0 (SD 118.5), p = 0.02821 |
| Time to peak | ~2 h | Mean spermidine tmax 53.13 h (SD 38.97) on placebo and 32.29 h (SD 31.78) on spermidine, p = 0.2317, from 50 samples per person across the study1 |
| Blood spermidine after spermidine-containing rolls | Not in the app's figures | In the nursing home trial (no placebo arm), median 41.65 ng/ml at the start in the wheat germ roll group (3.3 mg spermidine per roll, 6 times a week for 3 months), then 58.20, 57.20 and 59.40 ng/ml; the wheat bran roll group (1.9 mg per roll) stayed near 41 to 45 ng/ml4 |
The app's figures of a 6 hour half-life, 70% bioavailability and a 2 hour time to peak are not matched by any human figure in these sources, and the 15 mg/d crossover trial reports no increase in plasma spermidine; Senekowitsch and colleagues cite a rat study in which spermidine and spermine concentrations in whole blood peaked 1 h after oral administration.1 The app's note says tissue accumulation matters more than plasma half-life. The SmartAge authors offer a similar explanation for unchanged blood polyamines after 12 months, writing that polyamines "are likely rapidly taken up by solid tissues from blood after absorption from the intestinal lumen".5 Keohane and colleagues (Nutrition Research, 2024) report that 40 mg/day of a high-purity spermidine salt for up to 28 days produced no "substantial changes in serum and urine polyamine concentrations".9
Human studies
The table lists the human studies read, one row each; the analyses that follow cover the pivotal ones.
| Study and year | Design | People | Dose and length | Main result |
|---|---|---|---|---|
| Kiechl and colleagues, American Journal of Clinical Nutrition 20186 | Prospective community-based cohort of dietary intake; 341 deaths | 829 participants aged 45-84 y | Diet by food-frequency questionnaire in 1995, 2000, 2005 and 2010; follow-up 1995 to 2015 | All-cause deaths per 1000 person-years 40.5, 23.7 and 15.1 across thirds of rising intake; HR per 1-SD higher intake 0.76 (95% CI 0.67, 0.86) after adjustment for lifestyle factors, established predictors of mortality and other dietary features6 |
| Wirth and colleagues, Cortex 2018; Schwarz and colleagues, Aging 20187,10 | Randomised, placebo-controlled, double-blind phase IIa pilot; registered as NCT0275524611 | 30 cognitively intact adults aged 60 to 80 with subjective cognitive decline | Spermidine-rich plant extract for 3 months; 1.2 mg/day in the safety paper10 | Memory contrast mean .17 (95% CI -.01, .35), Cohen's d .77 (95% CI 0, 1.53); no differences from placebo in vital signs, weight, chemistry or haematology7,10 |
| Schwarz and colleagues (SmartAge), JAMA Network Open 20225 | Monocentre, randomised, double-masked, placebo-controlled phase 2b | 100 adults aged 60 to 90 with subjective cognitive decline (51 spermidine, 49 placebo) | Wheat germ extract with about 0.9 mg spermidine/d for 12 months | Primary outcome, mnemonic discrimination: between-group difference -0.03 (95% CI -0.11 to 0.05; P = .47); 89 of 100 completed5 |
| Pekar and colleagues, Wiener Klinische Wochenschrift 20214 | Randomised, double-blind, two-group, multicentre; the comparison group received a lower spermidine amount, not placebo | 92 residents aged 60 to 96 of six nursing homes in Styria, Austria | Grain rolls with wheat germ (3.3 mg spermidine per roll) or wheat bran (1.9 mg), 6 times a week for 3 months | In mild dementia, MMSE rose 2.23 points (p = 0.026) in the higher-dose group; the lower-dose group showed "consistent or declining cognitive performance"4 |
| Senekowitsch and colleagues, Nutrients 20231 | Randomised, placebo-controlled, triple-blinded, two-armed crossover | 12 healthy volunteers | 15 mg/d orally in two 5-day phases with a 9-day washout | Plasma spermidine unchanged (AUC p = 0.7819); plasma spermine AUC higher (p = 0.0282); no effect on salivary polyamines1 |
| Keohane and colleagues, Nutrition Research 20249 | Randomised, double-blind, within-subject, placebo-controlled; exploratory | 37 healthy men aged 50 to 70 | 40 mg/day of high-purity spermidine trihydrochloride for 7 and 28 days | No significant changes in clinical, lipid, chemistry or haematology measures versus placebo; no product-related adverse events reported9 |
| Alsaleh and colleagues, Aging Cell 20268 | Double-blind, randomised, placebo-controlled pilot after a third SARS-CoV-2 vaccine dose | 40 adults over 65 (tables list 20 spermidine, 18 placebo) | 6 mg/day for 13 weeks | Spermidine "significantly enhanced spike-specific IgG secretion" and other responses "specifically in non-responders"; exploratory, not powered for efficacy8 |
Deeper analysis: SmartAge (Schwarz and colleagues, JAMA Network Open, 2022)
Schwarz and colleagues report a monocentre phase 2b trial at an academic centre in Germany, run between January 2017 and May 2020, in people aged 60 to 90 with subjective cognitive decline recruited from health care facilities and through advertisements.5 The active product was a wheat germ extract of 750 mg a day in 6 capsules of 125 mg, corresponding to "approximately 0.9 mg spermidine", against 750 mg of microcrystalline cellulose.5 The primary outcome was change in mnemonic discrimination on the Mnemonic Similarity Task, with secondary outcomes across neuropsychological, behavioural and physiological measures.5 The adjusted mean change was -0.02 (95% CI -0.08 to 0.04) on spermidine and 0.01 (95% CI -0.04 to 0.06) on placebo, an adjusted treatment effect of -0.03 (95% CI -0.11 to 0.05; P = .47), and the full analysis set showed "no substantial treatment effect on any tested secondary parameter".5 In the per-protocol plus set (74 participants), soluble ICAM-1 differed by -56.2 ng/mL (95% CI -106.8 to -5.6; P = .03), which the authors call "a possible beneficial effect of the intervention", and Trail Making Test B time by 13.9 seconds (95% CI 1.5 to 26.2; P = .03), which they call "a negative effect of the intervention"; the per-protocol analysis of the primary outcome showed no statistically significant effect (P = .25).5 The authors note that "all exploratory findings would not be statistically significant after correction for multiple testing".5 Nineteen serious adverse events were documented, 7 in the spermidine group and 12 in the placebo group, all rated not related to the intervention; one participant in the spermidine group had a fatal or life-threatening event and none in the placebo group.5 There were 129 adverse events (58 spermidine, 71 placebo); musculoskeletal and connective tissue was "the only system organ class with substantially more AEs in the spermidine group (11 participants) compared with the placebo group (4 participants)".5 The authors give limitations including that amyloid status was "available from only 30% of participants" and that 12 months "might have been too short", and they suggest the 0.9 mg dose "might not have been sufficient".5 They add that people with previously diagnosed malignant neoplasms were excluded, so "the impact of spermidine supplementation on tumor growth could not be evaluated in this trial".5 Funding came from the German Federal Ministry of Education and Research (grant FKZ 01GQ1420B) among others, and "The Longevity Labs GmbH provided funds for supporting the development of spermidine-rich wheat germ extract during the conduct of the study".5 The funders are stated to have had "no role in the design and conduct of the study".5 Three authors (Madeo, Sigrist and Eisenberg) reported "equity interests in and advisory roles for The Longevity Labs GmbH", and Stekovic reported employment as chief executive officer of the company "during planning, initiation, and the time the trial was conducted".5 Dr Madeo also reported a US patent pending for technology related to spermidine.5
Deeper analysis: the 15 mg/d pharmacokinetic crossover (Senekowitsch and colleagues, Nutrients, 2023)
Senekowitsch and colleagues (Universities of Greifswald and Lübeck) describe their trial as the first investigation of the pharmacokinetics of oral spermidine supplementation.1 Twelve healthy volunteers took 15 mg/d of spermidine or placebo in two 5-day phases with a 9-day washout, and plasma and saliva spermidine, spermine and putrescine were measured by liquid chromatography-mass spectrometry.1 Plasma spermidine and putrescine did not differ from placebo; spermine AUC0-tlast rose (633.0 against 583.8 h·ng/mL, p = 0.0282) while spermine cmax did not differ significantly (9.45 against 7.19 ng/mL, p = 0.1294).1 Fasting morning spermine did not differ significantly between arms, though the authors note "a trend of a rising difference".1 In saliva, neither AUC, cmax nor tmax differed for the three polyamines.1 The authors' stated limitations are that it was exploratory, with no case number calculation, and that "it cannot be excluded that the study was not sufficiently powered to detect minor concentration changes".1 The paper states "This research received no external funding" and "The authors declare no conflict of interest".1 The text read does not report adverse event counts; its one use of "adverse" describes Snyder-Robinson syndrome, not the trial.1
Deeper analysis: the dietary intake cohort (Kiechl and colleagues, American Journal of Clinical Nutrition, 2018)
Kiechl and colleagues followed 829 participants aged 45 to 84 from 1995 to 2015, assessing diet with repeated dietitian-administered food-frequency questionnaires (2540 assessments); 341 deaths occurred.6 Deaths per 1000 person-years fell from 40.5 to 23.7 to 15.1 across thirds of increasing spermidine intake, and the adjusted hazard ratio per 1-SD higher intake was 0.74 (95% CI 0.66, 0.83), or 0.76 (95% CI 0.67, 0.86) after further adjustment for lifestyle factors, mortality predictors and other dietary features.6 The authors conclude that the findings "lend epidemiologic support to the concept that nutrition rich in spermidine is linked to increased survival in humans".6 The exposure is dietary spermidine measured by questionnaire, so it does not test a spermidine supplement; Senekowitsch and colleagues argue that such correlations do not consider "presystemic spermidine metabolism or dietary spermine intake".1 The record read for this study is the journal summary only, so the authors' limitations section is not described here; the listed grants are two British Heart Foundation grants.6
Deeper analysis: the nursing home trial (Pekar and colleagues, 2021)
Pekar and colleagues randomised 92 residents of six nursing homes to rolls containing wheat germ or wheat bran; the second group is described as a low-dose comparison, so the trial had no placebo arm.4 The authors calculate an additional 238 mg of spermidine on average in the wheat germ group and 137 mg in the wheat bran group over three months.4 The summary text reports tests on 85 subjects and a gain of 2.23 MMSE points (p = 0.026) in mild dementia, with phonematic fluency 1.99 "(p = 0.47)" as printed.4 The authors write that "a placebo effect cannot be completely excluded" in the lower-dose group and plan a one-year follow-up.4 A total of 85 participants were used for the analyses, and at follow-up vitamin B12 differed in the higher-dose group (p = 0.016), which the authors say "could mean that the regular intake of spermidine can cause a decrease of vitamin B12 in the organism", while noting that most persons were under proton pump inhibitor treatment.4 The study was "investigator driven and fully funded by the authors themselves", and the authors declare no competing interests.4
Deeper analysis: the vaccine response pilot (Alsaleh and colleagues, Aging Cell, 2026)
Alsaleh and colleagues, mainly from the University of Oxford, gave 6 mg of spermidine daily for 13 weeks or placebo to adults over 65 after a third SARS-CoV-2 vaccine dose, with safety as the primary endpoint.8 Full blood count and biochemistry were comparable between groups at weeks 0 and 2, and "There were no adverse events or adverse reactions associated with the nutraceutical".8 The authors state that the sample "was not powered for formal efficacy analyses", so the immune findings are exploratory.8 They list further limitations: the analysis was limited to naive and memory B cells because of blood sampling constraints, vaccine type could not be controlled so some participants had heterologous vaccination, and "the small sample size limits generalizability".8 The grants list includes "TLL The Longevity Labs GmbH", and the conflict statement says A.K.S. and T.E. consult for TLL, while "TLL has had no input into the trial design, results, analysis or manuscript".8
Deeper analysis: the 40 mg/day trial (Keohane and colleagues, Nutrition Research, 2024)
Keohane and colleagues gave 40 mg/day of high-purity spermidine trihydrochloride for 7 and 28 days to 37 healthy men aged 50 to 70, in an exploratory within-subject, placebo-controlled design.9 They report no significant changes in clinical, lipid, chemistry or haematology measures, "Compliance was high", and no product-related adverse events.9 Patrick Keohane and Rui Pereira are employees of Chrysea Labs, and the other authors "received funding from Chrysea Labs".9 The record read is the journal summary only, so the authors' limitations section is not described here; the registry listing for NCT05459961 names Chrysea Labs Lda as sponsor with status UNKNOWN.9
Doses reported in studies and on labels
| Source | Dose reported | Form, route and length | Comparator and number |
|---|---|---|---|
| Schwarz and colleagues 20225 | 750 mg extract a day, about 0.9 mg spermidine | 6 capsules of 125 mg, by mouth, 12 months | Microcrystalline cellulose; 100 randomised |
| Schwarz and colleagues 201810; registry entry11 | 1.2 mg/day; the registry lists 750 mg of plant extract per day | Spermidine-rich plant extract, 3 months | Placebo (750 mg potato starch per day in the registry); 30 adults |
| Pekar and colleagues 20214 | 3.3 mg spermidine per roll (wheat germ) or 1.9 mg per roll (wheat bran) | Rolls for breakfast 6 times a week, 3 months | The two groups compared with each other; 92 randomised |
| Alsaleh and colleagues 20268 | 6 mg/day | By mouth, 13 weeks | Placebo; 20 and 18 in the tables |
| Senekowitsch and colleagues 20231 | 15 mg/d | By mouth, two 5-day phases, 9-day washout | Placebo, crossover; 12 |
| Keohane and colleagues 20249 | 40 mg/day of high-purity spermidine trihydrochloride | By mouth, 7 and 28 days | Placebo, within-subject; 37 men |
| EU novel food specification3 | Spermidine 0.8 to 2.4 mg/g of extract; spermine 0.4 to 1.2 mg/g | Specification of the extract, not a daily amount | Not applicable |
| GRAS Notice 8892 | Extract at levels up to 2.7 g per serving in foods such as food bars and yogurt drinks; notifier's estimate of a maximum 12 mg spermidine per day | Intended food use stated by the notifier | Not applicable |
The app lists a typical range of 1 to 10 mg/day. The vaccine pilot authors write that "The European Food Safety Authority has concluded that supplemental spermidine is safe for adult populations at intakes of up to 6 mg/day"; that is their statement, and the EU regulation text gives specifications, not a daily limit.8
Side effects reported
Sources in this part
In SmartAge, the 19 serious adverse events were not rated related to the intervention, and the one fatal or life-threatening event was in the spermidine group; more musculoskeletal adverse events occurred in the spermidine group (11 participants against 4), mostly "age-related diseases and symptoms, such as osteoporosis, arthritis, gout attacks, and joint pain".5 The 3-month safety paper reported no differences in vital signs, weight, clinical chemistry, haematology or self-reported health, with compliance above 85%.10 The conflict statement of that paper says Drs Stekovic, Sigrist, Eisenberg and Madeo "have a financial interest in TLL".10 In that paper's mouse study, 28 days of repeated dosing gave no "morbidities or changes in behavior", and post mortem examination showed "no increase in tumorigenic and fibrotic events"; the same paper reports a 12% increase in relative kidney weight in female mice at the highest dose, and one serious adverse event in each human group, both rated unlikely or not related to the intervention.10 The SmartAge authors separately cite a preclinical mouse finding of "an increase of relative kidney weight after spermidine supplementation at high dosage", and list polyamine effects they call detrimental, including "potential enhancement of tumor growth".5 The 40 mg/day trial reported no product-related adverse events over up to 28 days.9
Bloodwork and markers
Sources in this part
Regulatory and anti-doping status
Commission Implementing Regulation (EU) 2020/443 of 25 March 2020 changed the specifications of the novel food "spermidine-rich wheat germ extract (Triticum aestivum)", raising the permitted cadaverine level from below 0.1 to 16.0 µg/g.3 The Commission considered that the change did "not alter the safety considerations that supported the authorisation".3 In the United States, TLL The Longevity Labs GmbH states in GRAS Notice 889 that it "has concluded that the use of spermidine rich wheat germ extract (SpermidineLife®) is Generally Recognized As Safe".2 That is the notifier's own conclusion; no FDA response letter was retrieved. The word spermidine does not appear in the text of the World Anti-Doping Agency's 2026 Prohibited List that was searched.12 The List's S0 class covers pharmacological substances not addressed by other sections of the List and "with no current approval by any governmental regulatory health authority for human therapeutic use".12
What is not known
Sources in this part
Among the PubMed and ClinicalTrials.gov records listed for the searches "spermidine supplementation randomized trial" and "spermidine", none was identified that reports a spermidine elimination half-life in people.1 The ClinicalTrials.gov listing includes an entry titled "Bioavailability of Spermidine in Healthy Males" (NCT06017219) with status UNKNOWN and no results identified in the search listing. The only randomised memory trial of 12 months in the records read found no between-group difference on its primary outcome, and its authors write that exploratory findings "need to be validated in future studies at higher dosage".5 The mortality association comes from dietary intake in observational cohorts; no randomised trial of mortality or of spermidine supplementation against death was identified in the records read.6 Whether the blood findings (unchanged spermidine, higher spermine in one 12-person study) reflect tissue exposure in people is not settled by these records, and Senekowitsch and colleagues argue doses below 15 mg/d are "rather unlikely" to have short-term effects, which sits against the app's 1 to 10 mg/day range.1
Frequently asked questions
What is the half-life of spermidine?
Is spermidine banned by WADA?
Does oral spermidine raise blood spermidine levels?
Did spermidine improve memory in the SmartAge trial?
Is spermidine authorised as a novel food in the EU?
Is higher spermidine intake linked to lower mortality?
What side effects were reported in spermidine trials?
The 12-month SmartAge trial reported 19 serious adverse events (7 spermidine, 12 placebo), all rated not related to the intervention.5 Musculoskeletal and connective tissue events were more frequent in the spermidine group (11 participants against 4).5 The 3-month safety paper reported one serious adverse event in each group, rated unlikely or not related to the intervention,10 and the 40 mg/day trial and the vaccine pilot reported no product-related adverse events.9,8
Has spermidine been tested in people with dementia?
Guides, tools and comparisons
References
- Senekowitsch S, et al. High-Dose Spermidine Supplementation Does Not Increase Spermidine Levels in Blood Plasma and Saliva of Healthy Adults: A Randomized Placebo-Controlled Pharmacokinetic and Metabolomic Study. Nutrients 2023. PMC10143675
- TLL The Longevity Labs GmbH. Generally Recognized As Safe (GRAS) assessment of spermidine rich wheat germ extract. GRAS Notice (GRN) No. 889, US Food and Drug Administration. FDA GRAS notice 889
- European Commission. Implementing Regulation (EU) 2020/443 of 25 March 2020 authorising the change of the specifications of the novel food spermidine-rich wheat germ extract (Triticum aestivum). EUR-Lex. EUR-Lex 2020/443
- Pekar T, et al. The positive effect of spermidine in older adults suffering from dementia: first results of a 3-month trial. Wien Klin Wochenschr 2021. PMC8116233
- Schwarz C, et al. Effects of Spermidine Supplementation on Cognition and Biomarkers in Older Adults With Subjective Cognitive Decline: A Randomized Clinical Trial. JAMA Netw Open 2022. PMC9136623
- Kiechl S, et al. Higher spermidine intake is linked to lower mortality: a prospective population-based study. Am J Clin Nutr 2018. PMID 29955838
- Wirth M, et al. The effect of spermidine on memory performance in older adults at risk for dementia: A randomized controlled trial. Cortex 2018. PMID 30388439
- Alsaleh G, et al. Spermidine Mitigates Immune Cell Senescence and Boosts Vaccine Responses in Healthy Older Adults-A Pilot Study. Aging Cell 2026. PMC13240347
- Keohane P, et al. Supplementation of spermidine at 40 mg/day has minimal effects on circulating polyamines: An exploratory double-blind randomized controlled trial in older men. Nutr Res 2024. PMID 39405978
- Schwarz C, et al. Safety and tolerability of spermidine supplementation in mice and older adults with subjective cognitive decline. Aging (Albany NY) 2018. PMC5807086
- ClinicalTrials.gov. NCT02755246. Polyamine-enriched Diet in Healthy Older Adults With Subjective Cognitive Decline. Charite University, Berlin. NCT02755246
- World Anti-Doping Agency. World Anti-Doping Code International Standard: Prohibited List 2026. WADA list